|
Patients (n, XVd vs Vd)
|
Median PFS, months (95% CI)
|
HR (95% CI)
|
P value
|
|---|
|
XVd
|
Vd
|
|---|
|
1 prior line (99 vs 99)
|
16.62 (13.24, NR)
|
10.68 (7.26, 16.39)
|
0.6295 (0.4133, 0.9586)
|
0.0148
|
|
2–3 prior lines (96 vs 108)
|
11.76 (7.39, NR)
|
9.43 (6.83, 9.69)
|
0.6949 (0.4760, 1.0147)
|
0.0295
|
|
Lenalidomide naïve (118 vs 130)
|
16.62 (12.98, NR)
|
10.61 (8.44, 15.41)
|
0.6619 (0.4548, 0.9634)
|
0.0150
|
|
Lenalidomide treated (77 vs 77)
|
9.59 (6.70, NR)
|
7.23 (4.93, 9.69)
|
0.6348 (0.4148, 0.9714)
|
0.0177
|
|
PI naïve (47 vs 48)
|
NR (NR, NR)
|
9.69 (8.44, NR)
|
0.2585 (0.1116, 0.5988)
|
0.0003
|
|
PI treated (148 vs 159)
|
11.73 (7.95, 15.21)
|
9.43 (7.06, 10.71)
|
0.7839 (0.5791, 1.0612)
|
0.0576
|
|
IMiD refractory (74 vs 86)
|
13.93 (6.70, NR)
|
8.44 (5.78, 9.56)
|
0.5752 (0.3753, 0.8816)
|
0.0051
|
|
Prior bortezomib only as induction for ASCT (37 vs 30)
|
13.14 (11.73, NR)
|
9.43 (5.75, NR)
|
0.5807 (0.2860, 1.1791)
|
0.0639
|
|
ASCT (76 vs 63)
|
16.56 (9.59, NR)
|
9.43 (5.91, 10.87)
|
0.5527 (0.3411, 0.8955)
|
0.0074
|
|
No ASCT (119 vs 144)
|
13.24 (10.18, NR)
|
9.56 (8.11, 13.60)
|
0.7239 (0.5111, 1.0252)
|
0.0341
|
- ASCT autologous stem cell transplant, CI confidence interval, IMiD immunomodulatory drug, NR not reached, ORR overall response rate, PFS progression-free survival, PI proteasome inhibitor
